Heghine Khachatryan: A Valuable Educational Resource on Inhibitor Development
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared European Association for Haemophilia and Allied Disorders (EAHAD)’s post on LinkedIn, adding:
“An outstanding educational initiative.
As gene therapy continues to transform haemophilia care, a deeper understanding of inhibitor development remains fundamental to ensuring both efficacy and long-term safety.
Thank you for this valuable educational resource.”
European Association for Haemophilia and Allied Disorders (EAHAD) shared a post on LinkedIn:
“Missed our latest Gene Therapy online session or want to rewatch it?
The full replay of ‘Inhibitor Development in Gene Therapy for Haemophilia’ is now available on the EAHAD Academy.
And stay tuned for our next Gene Therapy webinar!”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 8, 2026, 04:28Jeff Molter: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 04:23Barbara Adams Krolak: Women and Blood Clots Are We Missing the Warning Signs
-
Oct 8, 2026, 04:10Rutendo Muzambi: Hospital Admission Patterns and Care Disparities in Sickle Cell Disease
-
Oct 8, 2026, 03:50Olfat Berro: Redefining the Future of Haemophilia A
-
Oct 8, 2026, 03:35Tasnia Tarana: Heavy Menstrual Bleeding When the Cause Is Not in the Uterus
-
Oct 8, 2026, 03:28Kian Haseli: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 03:20Sthanu Subramanian: Leukopenia in Sepsis A Marker of Severe Disease
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target